Gestion des toxicités des immunothérapies du cancer : challenges et « rechallenges » pour les (jeunes) internistes

This publication has 29 references indexed in Scilit:

• Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review
  Seminars in Cancer Biology, 2020
• Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study
  Arthritis & Rheumatology, 2019
• Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance
  Journal for ImmunoTherapy of Cancer, 2019
• A Multidisciplinary Toxicity Team for Cancer Immunotherapy–Related Adverse Events
  Journal of the National Comprehensive Cancer Network, 2019
• Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).
  Journal of Clinical Oncology, 2019
• Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
  Annals of Intensive Care, 2019
• Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor–induced inflammatory arthritis
  Clinical Rheumatology, 2019
• Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis
  JAMIA Open, 2018
• Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
  European Journal of Cancer, 2018
• Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge
  La Revue de Médecine Interne, 2017